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OBJECTIVES:To validate a software, for an optical pencil toll, to
calculate psoriasis patients’ Body Surface Area (BSA) and to
demonstrate that the new developed method is been valid and
reliable to quantify the BSA.METHODS:Multicentre prospective
study at Dermatology centres (Five Spanish Hospitals and one
Portuguese Hospital). In each hospital two dermatologists visited
the same patients twice (second visit 3 days after ﬁrst). 60 derma-
tologists included10 consecutive patients with psoriasis. Socio-
demographical and clinical variables (PASI, time since diagnosis,
current treatment) and BSA scoreswere colleted for each patient in
the two visits. To calculate BSA scores traditional method (visual
grading following the nine rule of Wallace method’s) and the
optical pencil method (BSA software developed) were used. Inter-
intraobservers reliability, variability between BSA scores regard-
ing the new tool, versus the traditional method, and the tool’s
usefulness will be assessed. RESULTS: Fifty-six patients were
included.Mean (SD) agewas 48.93 (16.76) years.Mean (SD) time
since diagnosis was 18.77 (14.28). Pearson’s correlation coefﬁ-
cient between both methods was 0.91 (p < 0.01). Intraobserver
correlation for each of the methods was 0.91. The correlation
among both methods was in the ﬁrst visit 0.92 and 0.90 in the
second visit. The ICC was higher than 0.85 independently of
which of the two methods were used ﬁrstly. The investigators
considered that the new method is easy to use (94%), it guides
towards the disease management (64%) and standardizes the
calculation of the body surface area (86.4%). CONCLUSION:
These results can prove that the software to assess BSA has shown
to be valid to be used both in clinical practice and in clinical
studies. Therefore, the optical pencil method to quantify BSA can
be used as standard for the assessment of involved body surface
area in the management of psoriatic patients.
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OBJECTIVES: The introduction of novel therapeutic options for
psoriasis has raised managed care’s interest in controlling costs
associated with dermatological treatments. Prior authorization
(PA) can be a successful way of managing costs. However, expe-
rience with topical treatments for acne suggests that PA may not
be cost-effective. The role of managed care in dermatology and
the potential impact of PA requirements for novel topical thera-
pies for psoriasis are considered. METHODS: Using a model
based on recent nationally representative survey data (NAMCS),
total annual cost estimates for a managed care organization to
cover psoriasis treatment with a topical agent with or without PA
requirements were calculated and compared. Costs for treatment
and administrative costs associated with PA processes were
included. The model assumed 68,000 insured patients required
treatment (with an additional 1% to account for abuse/misuse),
an average wholesale price of $100 per prescription (each pre-
scription ﬁlled 4x/year), and a cost of $20 to process each PA
request. RESULTS: The total annual costs were $28,573,600
when PA was required and $27,472,000 when PA was not
required. Thus there was a total annual loss to the managed care
organization of $1,101,600 associated with PA requirements.
CONCLUSION: Requiring PA for novel topical treatments for
psoriasis, such as the new 2-compound product containing cal-
cipotriene and betamethasone dipropionate, is not likely to be
cost-effective for a managed care organization.
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OBJECTIVES: In an increasing number of European countries
patient-deﬁned beneﬁt is considered important in the valuation
of therapy. So far, most procedures used for beneﬁt assessment do
not cover the broad spectrum of beneﬁts relevant to patients nor
do they allow for an individual weighting of preferences. In this
context a patient-reported beneﬁt questionnaire was developed
and validated. METHODS: Initially, open questioning of n = 100
dermatological patients generated a pool of 213 beneﬁt items
which were converted into a 24 item-list by an expert panel of
dermatologists, psychologists and patients. This pilot version of
the questionnaire was evaluated in a group of n = 500 patients
with 10 dermatological diagnoses. Basic principle of the instru-
ment is pre/post data-collection. Prior to therapy, individually
perceived needs (Patient Needs Questionnaire, PNQ) are
obtained: For each of the 24 standardized items patients rate its
importance on a Likert scale ranging from 0 (“not important at
all” resp. “doesn’t apply to me”) to 4 (“very important”). At the
end of therapy the degree to wich these beneﬁts (Patient Beneﬁt
Questionnaire, PBQ) were achieved is assessed using the same list
with scaling from 0 (“therapy didn’t help at all”) to 4 (“helped a
lot”). To compose a single outcome parameter a formula was
developed by weighting the PBQ with their respective PNQ-
items. This “Patient Beneﬁt Index” (PBI) also ranges from 0 to 4.
RESULTS: Besides good acceptance and feasibility the PBI
showed construct validity and the PNQ a high internal consis-
tency with Cronbach’s alpha > 0.94. Diagnostic groups presented
different and clinically plausible outcome-patterns: Whereas the
PBI was rather low for all vitiligo-therapies (mean = 1.03, SD
1.13, n = 711) wound-patients undergoing vacuum-assisted
therapy (n = 172) showed a mean PBI of 2.75 (SD = 0.89). CON-
CLUSION: The PBI is a valid and reliable instrument to obtain
patient-deﬁned and individually weighted therapeutic beneﬁts in
clinical and public health studies.
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OBJECTIVES: The Dermatology Life Quality Index (DLQI) is a
validated and widely used patient reported outcomes instrument.
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Cost-utility analyses however require preference based measures
to calculate quality adjusted life years. This study aimed to
estimate the association between health utility and DLQI
response in patients with chronic plaque psoriasis. METHODS:
A consecutive sample of all patients treated for a primary diag-
nosis of psoriasis at Llandough Hospital, Cardiff, UK over a
period of two years were identiﬁed from the hospital record
system. All patients were sent the Health Outcomes Data Reposi-
tory (HODaR) survey including the EQ-5D and DLQI instru-
ments. Individual patient utility was estimated from EQ-5D
responses using the standard UK scoring algorithm. A predictive
regression model was built to estimate EQ-5D utility scores from
patient DLQI responses. RESULTS: A total of 94 psoriasis
patients responded to the survey. Fifty percent of patients were
female, and the mean age was 50.0 years (range from <10 to >80
years). Patients had been diagnosed with psoriasis for a mean of
15.6 years. Over the previous year 20.4% of patients had at least
one inpatient admission and 66.0% at least one outpatient atten-
dance for their psoriasis. Eighteen patients (19%) reported that
they were currently received treatment with a systemic agent or
with PUVA. The regression model found DLQI score to be sig-
niﬁcantly related to the EQ5D utility score. Estimated utility
at zero DLQI, the best possible response, was 0.956 (standard
error 0.039, p < 0.001) and each one point rise in DLQI was
associated with a decrease of 0.02548 (standard error 0.004,
p < 0.001) in estimated utility. The model described 27% of the
variation in the EQ5D data for the survey respondents.
CONCLUSION: It was possible to estimate utility from patient
DLQI score in a population with psoriasis requiring hospital
management.
PSK12
PATIENT REPORTED OUTCOMES IN PSORIASIS
Garcia-Diez A1, Ferrandiz C2, Bermudez-Rey L3, Espallardo O4,
Lizan L5, Badia X5
1Hospital Universitario La Princesa, Madrid, Spain, 2Hospital Germans
Trias i Pujol, Badalona, Spain, 3Serono, Madrid, Spain, 4Merck Serono,
Spain, Madrid, Madrid, Spain, 5IMS Health, Barcelona, Spain
OBJECTIVES: To know the repercussion of the moderate-severe
psoriasis on the health-related quality of life (HRQoL), the
health state utilities, the direct costs and the health resources
employees in the last year. METHODS: An observational (natu-
ralistic) study conducted at Dermatology centres in Spain and
Portugal. A total of 332 dermatologists included 10 consecu-
tive patients with moderate to severe psoriasis. The case report
form includes information about the Psoriasis Disability Index
(PDI), as well as variables of severity: Body surface area (BSA)
and Psoriasis Area and Severity Index (PASI). Health state utili-
ties were assessing by the Time Trade-off and Willingness to pay
methods. Data collected also include the direct cost in treatments
and days of sick leave, number of medical visits, hospitalization
days and emergency visits in the last year. RESULTS: 3320
patients were assessed. Mean BSA involvement was 23% (95%
CI: 22.2–23.3%) and mean PASI score was 14.3 (95% CI: 13.9–
14.6%). The mean value of the PDI was 8.93 (IC95% 7.83–
9.21). There was a consistent decrease in HRQoL with increase
in disease severity. The mean amount of remaining life that
patients were willing to sacriﬁce to be free from psoriasis was 25
months (95% CI: 23.4–26.8) and the mean proportion of
monthly income that were willing to pay was 29% (95% CI:
28.1–30.1), with the amount of time or income increasing with
disease severity. In 89% of patients, psoriasis represented a mean
direct treatment expense of 816 € yearly. CONCLUSION: The
psoriasis causes a negative impact in the HRQoL and in the
patient’s budget. This study establish a relationship between
the severity of psoriasis and the amount of money or time of
remaining life that patients are willing to pay or sacriﬁce, respec-
tively, to be free of psoriasis.
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OBJECTIVES: The OSSAS and OSIS are patient reported
outcome measures developed using focus groups to assess facial
Oily Skin (OS) severity and the psychosocial impact of oily skin,
respectively. This study examines the validity and reliability of
these measures in a cross-sectional study. METHODS: The
OSSAS, OSIS and concurrent measures (Skindex and AcneQoL)
were administered to 202 OS patients at seven sites across the
USA. A sub-group of 152 patients returned 1–2 weeks later for
test-retest reliability evaluation. RESULTS: Of the 202 partici-
pants, 72.8% were female; 64.4% had acne in addition to OS.
Item reduction analyses resulted in a 14 item OSSAS with ‘Sen-
sations’ (5 items), ‘Tactile’ (3 items) and ‘Visual’ (4 items)
domains, a single blotting item, and a single overall oiliness item.
The 6 item OSIS includes Annoyance (3 items) and Self-Concept
(3 items) domains. Conﬁrmatory factor analysis provided
support for the construct validity of the ﬁnal item-scale struc-
tures. The OSSAS and OSIS scales had acceptable item conver-
gent validity (item-scale correlations >0.40) and ﬂoor and ceiling
effects (<20%). Cronbach’s alpha coefﬁcients ranged from 0.83–
0.89 for the OSSAS and 0.82–0.87 for the OSIS, demonstrating
excellent internal consistency. The a priori criterion for test-retest
reliability (ICC  0.7) was met for one of the three OSSAS
domains and one of the two OSIS domains. Correlations of the
Skindex-29 and Acne-QoL scales with the OSSAS (range: -0.08–
0.38) and OSIS (range: 0.37–0.73) domain scores met content
expectations for these scales. OSSAS and OSIS domains distin-
guished among groups of patients who differed in terms of both
patient reported facial OS severity (p < 0.0001) and patient
reported bother associated with OS (p < 0.0001). CONCLU-
SION: The OSSAS and OSIS provide valid self-report measures
of facial OS severity and the emotional impact of OS, respec-
tively. Test-retest reliability and responsiveness of these measures
require further evaluation.
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OBJECTIVES: Varenicline (Champix®) is a new drug indicated
for smoking cessation. The objective was to analyse the efﬁciency
of varenicline compared with bupropion, NRT (nicotine replace-
ment therapy) and no pharmacological treatment in Spain.
METHODS: A Markov model was developed to analyse the
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